Literature DB >> 25128848

Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function.

Yukitoshi Izumi1, Charles F Zorumski2.   

Abstract

Ketamine is a non-competitive N-methyl-d-aspartate receptor (NMDAR) antagonist of interest in neuropsychiatry. In the present studies, we examined the effects of subanesthetic, low micromolar ketamine on excitatory postsynaptic potentials (EPSPs), population spikes (PSs) and synaptic plasticity in the CA1 region of rat hippocampal slices. Ketamine acutely inhibited NMDAR-mediated synaptic responses with half-maximal effects near 10 μM. When administered for 15-30 min at 1-10 μM, ketamine had no effect on baseline dendritic AMPA receptor-mediated EPSPs, but persistently enhanced somatic EPSPs in the pyramidal cell body layer and augmented PS firing. Acute low micromolar ketamine also had no effect on the induction of long-term potentiation (LTP) but blocked long-term depression (LTD). Following 30 min administration of 1-10 μM ketamine, however, a slowly developing and persistent form of LTP inhibition was observed that took two hours following ketamine washout to become manifest. This LTP inhibition did not result from prolonged or enhanced NMDAR inhibition during drug washout. Effects of low ketamine on somatic EPSPs and LTP were not mimicked by a high ketamine concentration that completely inhibited NMDARs, and both of these effects were blocked by co-administration of low ketamine with a low concentration of the competitive NMDAR antagonist, 2-amino-5-phosphonovalerate or inhibitors of nitric oxide synthase. These results indicate that concentrations of ketamine relevant to psychotropic and psychotomimetic effects have complex metaplastic effects on hippocampal function that involve activation of unblocked NMDARs during ketamine exposure.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Memory; Modulation; NMDA receptor; Nitric oxide; Psychosis; Synaptic plasticity

Mesh:

Substances:

Year:  2014        PMID: 25128848      PMCID: PMC4188808          DOI: 10.1016/j.neuropharm.2014.08.002

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  65 in total

1.  Ethanol enhances neurosteroidogenesis in hippocampal pyramidal neurons by paradoxical NMDA receptor activation.

Authors:  Kazuhiro Tokuda; Yukitoshi Izumi; Charles F Zorumski
Journal:  J Neurosci       Date:  2011-07-06       Impact factor: 6.167

2.  Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors.

Authors:  Ezio Bettini; Anna Sava; Cristiana Griffante; Corrado Carignani; Alberto Buson; Anna Maria Capelli; Michele Negri; Filippo Andreetta; Sergio A Senar-Sancho; Lorena Guiral; Francesca Cardullo
Journal:  J Pharmacol Exp Ther       Date:  2010-09-01       Impact factor: 4.030

3.  The NADPH oxidase NOX2 controls glutamate release: a novel mechanism involved in psychosis-like ketamine responses.

Authors:  Silvia Sorce; Stefania Schiavone; Paolo Tucci; Marilena Colaianna; Vincent Jaquet; Vincenzo Cuomo; Michel Dubois-Dauphin; Luigia Trabace; Karl-Heinz Krause
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

4.  Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis.

Authors:  Kazuhiro Tokuda; Kazuko A O'Dell; Yukitoshi Izumi; Charles F Zorumski
Journal:  J Neurosci       Date:  2010-12-15       Impact factor: 6.167

5.  Information processing deficits and nitric oxide signalling in the phencyclidine model of schizophrenia.

Authors:  Erik Pålsson; John Lowry; Daniel Klamer
Journal:  Psychopharmacology (Berl)       Date:  2010-08-28       Impact factor: 4.530

6.  NMDA receptors, mGluR5, and endocannabinoids are involved in a cascade leading to hippocampal long-term depression.

Authors:  Yukitoshi Izumi; Charles F Zorumski
Journal:  Neuropsychopharmacology       Date:  2011-10-12       Impact factor: 7.853

7.  Anesthetic ketamine impairs rats' recall of previous information: the nitric oxide synthase inhibitor N-nitro-L-arginine methylester antagonizes this ketamine-induced recognition memory deficit.

Authors:  Antonios Boultadakis; Nikolaos Pitsikas
Journal:  Anesthesiology       Date:  2011-06       Impact factor: 7.892

8.  Effects of the nitric oxide synthase inhibitor L-NAME on recognition and spatial memory deficits produced by different NMDA receptor antagonists in the rat.

Authors:  Antonios Boultadakis; Nikolaos Pitsikas
Journal:  Neuropsychopharmacology       Date:  2010-07-21       Impact factor: 7.853

9.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

10.  Distinct modes of AMPA receptor suppression at developing synapses by GluN2A and GluN2B: single-cell NMDA receptor subunit deletion in vivo.

Authors:  John A Gray; Yun Shi; Hiroshi Usui; Matthew J During; Kenji Sakimura; Roger A Nicoll
Journal:  Neuron       Date:  2011-09-21       Impact factor: 18.688

View more
  22 in total

1.  Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.

Authors:  Ji-Woon Kim; Lisa M Monteggia
Journal:  Behav Brain Res       Date:  2019-11-21       Impact factor: 3.332

2.  Ketamine reduces deleterious consequences of spreading depolarizations.

Authors:  Katelyn M Reinhart; C William Shuttleworth
Journal:  Exp Neurol       Date:  2018-04-10       Impact factor: 5.330

3.  Ketamine: NMDA Receptors and Beyond.

Authors:  Charles F Zorumski; Yukitoshi Izumi; Steven Mennerick
Journal:  J Neurosci       Date:  2016-11-02       Impact factor: 6.167

Review 4.  Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders.

Authors:  Ege T Kavalali; Lisa M Monteggia
Journal:  Neuron       Date:  2020-06-03       Impact factor: 17.173

5.  Neonatal exposure of ketamine inhibited the induction of hippocampal long-term potentiation without impairing the spatial memory of adult rats.

Authors:  Dongyong Guo; Jianhui Gan; Tao Tan; Xin Tian; Guolin Wang; Kevin Tak-Pan Ng
Journal:  Cogn Neurodyn       Date:  2018-02-22       Impact factor: 5.082

Review 6.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 7.  24(S)-Hydroxycholesterol as a Modulator of Neuronal Signaling and Survival.

Authors:  Min-Yu Sun; Andrew J Linsenbardt; Christine M Emnett; Lawrence N Eisenman; Yukitoshi Izumi; Charles F Zorumski; Steve Mennerick
Journal:  Neuroscientist       Date:  2015-01-27       Impact factor: 7.519

Review 8.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

9.  Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.

Authors:  Allie J Widman; Lori L McMahon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-12       Impact factor: 11.205

10.  Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling.

Authors:  Eléonore Beurel; Steven F Grieco; Celeste Amadei; Kimberlee Downey; Richard S Jope
Journal:  Bipolar Disord       Date:  2016-09-30       Impact factor: 6.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.